A randomized study to compare biodegradable self-reinforced polyglycolic acid spiral stents to suprapubic and indwelling catheters after visual laser ablation of the prostate.
OBJECTIVE
A randomized controlled study was done to evaluate the efficacy of the self-reinforced polyglycolic acid spiral stent compared to a suprapubic catheter, and combined suprapubic and indwelling catheters in the prevention of urinary retention after visual laser ablation of the prostate.


METHODS
We studied 72 men with benign prostatic hyperplasia who underwent placement of a suprapubic catheter and visual laser ablation of the prostate. In 27 men in group 1 the self-reinforced polyglycolic acid spiral stent was inserted into the prostatic urethra after visual laser ablation of the prostate, while 23 in group 2 received no other devices. In 22 men in group 3 an indwelling catheter was left in situ for an average of 6.5 days.


RESULTS
Voiding began 1 or 2 days postoperatively in 20 of 27 patients (median 1 day) in group 1, and 8 of 23 (median 6 days) in group 2. In 16 of 22 men in group 3 voiding began 1 or 2 days (median 6) after removal of the indwelling catheter. Improvements in patient weighted symptom score, mean peak urinary flow rate and post-void residual volume were significant (p < 0.001) at 6 months of followup in all groups. The overall infection rate was 30%.


CONCLUSIONS
The self-reinforced polyglycolic acid spiral stent is superior to the suprapubic catheter alone, and to combined indwelling and suprapubic catheters for the treatment of postoperative urinary retention after laser therapy, offering possibilities for shorter catheterization time.
Pétas
A
A
Department of Urology, Helsinki University Central Hospital, Finland.
Talja
M
M
Tammela
T
T
Taari
K
K
Lehtoranta
K
K
Välimaa
T
T
Törmälä
P
P
D000368:Aged; D000369:Aged, 80 and over; D001673:Biodegradation, Environmental; D002408:Catheters, Indwelling; D004867:Equipment Design; D005500:Follow-Up Studies; D006801:Humans; D053685:Laser Therapy; D008297:Male; D008875:Middle Aged; D011100:Polyglycolic Acid; D011468:Prostatectomy / Q000009:adverse effects / Q000379:methods*; D015607:Stents; D016055:Urinary Retention / Q000209:etiology / Q000517:prevention & control*
D011100:Polyglycolic Acid